Sector News

Sanofi sells another castoff to private equity firm after last year’s $2.2B Zentiva deal

September 11, 2019
Life sciences

Sanofi India is selling a 32-year-old plant in Ankleshwar to a private equity firm as Sanofi focuses in the country on branded drugs like multiple sclerosis drug Aubagio. (Sanofi India)

Private equity investor Advent International has picked up another piece of Sanofi that it is shedding as the French drugmaker sharpens its focus on branded drugs. After laying out $2.2 billion for Sanofi’s generics operation Zentiva last year, it has followed up with a much smaller deal.

Sanofi India today announced the sale of a manufacturing plant in Ankleshwar, Gujarat to Advent’s Zentiva for Rs 2,617 million ($36.5 million). The 32-year-old plant produces intermediates and formulations and has an annual capacity for more than 6 billion tablets.

“Sanofi’s long-term strategy is to focus on manufacturing Sanofi branded products. Given that the two companies share similar values and commitment towards serving patients and their employees, the Board of Directors of Sanofi India Limited approved this transaction in the long-term interest of all stakeholders.” Rajaram Nayayanan, managing director of the Sanofi company, said in a statement.

The Ankleshwar plant, the oldest of Sanofi India, produces products such as pain reliever Combiflam, hay fever treatment Allegra and diabetes treatment Amary. Production of those drugs will be transferred to other Sanofi plants, the company said.

Advent, which buys pharma and other businesses globally, last year completed a $2.2 billion deal for Zentiva, after Sanofi looked for a buyer for a couple of years. Sanofi had acquired control of the Czech generics operation in 2008 for $2.6 billion.

Advent has been mentioned as among potential buyers for assets that GlaxoSmithKline and Pfizer will shed to satisfy regulators as they prepare to merge their consumer drug businesses later this year.

By Eric Palmer

Source: Fierce Pharma

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

September 13, 2019

One of the largest pharma companies in the world just got into cannabis

Life sciences

LinkedIn Twitter FacebookAccording to information procured exclusively ahead of a formal announcement Friday, a subsidiary of NYSE-traded giant Teva Pharmaceuticals has signed a deal with medical cannabis company Canndoc to […]

September 12, 2019

UK Government confirms disruption to medicines in event of no-deal Brexit

Life sciences

LinkedIn Twitter FacebookA document published by the UK Government laying out the worst case scenario if the UK leaves the European Union (EU) with no deal on 31st October stated […]

September 11, 2019

Changing of the guard at Swiss biotech Vifor; nabs Sanofi exec as new CMO

Life sciences

LinkedIn Twitter FacebookVifor Pharma is losing a chief commercial officer but gaining a new chief medical officer in the form of Sanofi’s Klaus Henning Jensen. Jensen joins from the French […]

Subscribe to our Weekly Newsletter

We're easy to reach